| Preview | Issue Date | Title / Name | Author(s) | Type |
| 2021 | MO01.39 Liposomal Irinotecan in Adults with Small Cell Lung Cancer who Progressed on Platinum-Based Therapy: Subgroup Analyses by Platinum Sensitivity | Spigel, David R.; Paz-Ares, Luis G.; Chen, Yuanbin; Jove, Maria; Juan-Vidal, Oscar, et al | Conference Paper | |
| 2019 | OA03.03 Initial Efficacy and Safety Results of Irinotecan Liposome Injection (nal-IRI) in Patients with Small Cell Lung Cancer | Paz-Ares Rodriguez, L.; Spigel, David R.; Chen, Yuanbin; Jove, Maria; Juan, O., et al | Conference Paper | |
| 2021 | P48.14 RESILIENT Part 2: A phase 3 Study of Liposomal Irinotecan in Patients with Small-Cell Lung Cancer in the Second-Line Setting | Paz-Ares, Luis; Spigel, David R.; Chen, Yuanbin; Jove, Maria; Juan-Vidal, Oscar, et al | Conference Paper | |
| May-2022 | RESILIENT part 1: a phase 2 dose-exploration and dose-expansion study of second-line liposomal irinotecan in adults with small cell lung cancer | Spigel, David R.; Paz-Ares, Luis; Moore, Yan; Zhang, Bin; Dowlati, Afshin, et al | Journal Article | |
| 2020 | RESILIENT part 1: Pharmacokinetics of second-line (2L) liposomal irinotecan in patients with small cell lung cancer (SCLC) | Ponce, Santiago; Brendel, K.; Spigel, David R.; Chen, Yuanbin; Jove Casulleras, M., et al | Conference Paper | |
| 2020 | RESILIENT part I, an open-label, safety run-in of liposomal irinotecan in adults with small cell lung cancer (SCLC) who have progressed with platinum-based first-line (1L) therapy: Subgroup analyses by platinum sensitivity | Spigel, David R.; Paz-Ares, Luis G.; Chen, Yuanbin; Jove, Maria; Juan-Vidal, Oscar, et al | Conference Paper | |
| 2020 | RESILIENT part II: An open-label, randomized, phase III study of liposomal irinotecan injection in patients with small-cell lung cancer who have progressed with platinum-based first-line therapy | Spigel, David R.; Paz-Ares, Luis G.; Moore, Yan; Zhang, Bin; Dowlati, Afshin, et al | Conference Paper | |
